半乳糖凝集素3与慢性肾脏病风险评估  

Galectin-3 and chronic kidney disease

作　　者：张志宏[1] 刘志红[1] 

机构地区：[1]南京军区南京总医院肾脏科国家肾脏疾病临床医学研究中心全军肾脏病研究所,南京210016

出　　处：《肾脏病与透析肾移植杂志》2015年第5期459-462,492,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：南京军区南京总医院院管课题(2013038)

摘　　要：慢性肾脏病(CKD)是世界性的公共卫生问题,我国CKD发生率逐年递增。除进展至终末期肾病(ESRD)外,CKD并发心血管疾病的风险显著升高。CKD的本质是肾组织慢性炎症和纤维化,涉及众多代谢产物和信号通路。半乳糖凝集素3(Gal-3)是体内一种重要的多功能蛋白质,具有广泛的病理生理意义。新近的多项研究发现Gal-3与心肾疾病的发生和进展关系紧密。本文就Gal-3在CKD心脏、肾脏事件风险评估中的认识进展作一综述。China has a high prevalence of chronic kidney disease（ CKD）. CKD imposes an enormous burden on public health resources for the reasons of development of end-stage renal disease（ ESRD） and complications of cardiovascular diseases. Galectin-3 is a member of the multifunctional proteins comprising soluble β-galactoside-binding lectins that have regulatory roles in fibrogenesis,inflammation,tissue repair and cell proliferation. This review will focus on the relevant research progresses of Galectin-3 in CKD.

关 键 词：慢性肾脏病 心血管疾病 半乳糖凝集素3 

分 类 号：R692[医药卫生—泌尿科学]